Dr. Reddys Laboratories is currently trading at Rs. 4011.55, up by 15.65 points or 0.39% from its previous closing of Rs. 3995.90 on the BSE.
The scrip opened at Rs. 4000.00 and has touched a high and low of Rs. 4018.65 and Rs. 3995.90 respectively.
The BSE group ‘A’ stock of face value Rs. 5 has touched a 52 week high of Rs. 4189.35 on 10-Jun-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.
Last one week high and low of the scrip stood at Rs. 4134.00 and Rs. 3966.75 respectively. The current market cap of the company is Rs. 66419.24 crore.
The promoters holding in the company stood at 26.75%, while Institutions and Non-Institutions held 44.50% and 14.65% respectively.
Dr Reddy’s Laboratories is expecting to launch 25 products in the US market in the current financial year (FY21). The drug major has also earmarked a capital expenditure (capex) of Rs 1,000 crore for finding various projects during the ongoing financial year.
Besides, the drug maker is also working on various biosimilar products, including, the Rituximab Phase III trial is progressing as per plan. And, in parallel, it is working on multiple other biosimilar products, which are at different stage of development.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas
